• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
cnb1439_3rs-project_nav-ad_v2
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

News

September 1, 2025

CN Bio adds computational modelling capabilities to ADME services for enhanced bioavailability profiling

CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced

Category iconPress releases Tag iconADME

July 15, 2025

Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies

Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins,

Category iconBlog

July 7, 2025

NIH to prioritize human-based research technologies & reduce animal use in research

During the FDA-NIH Workshop: Reducing Animal Testing, held on July 7, 2025, Dr. Nicole Kleinstreuer, Acting NIH Deputy Director for Program

Category iconPress releases

June 25, 2025

CN Bio to participate in 3Rs Collaborative-led project with FDA to build confidence in Liver MPS for DILI

Building Confidence in MPS for Regulatory Applications!   At the intersection of innovation, collaboration, and science lies an exciting new

Category iconPress releases

June 10, 2025

CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two

Category iconPress releases

May 20, 2025

CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea

Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion CN Bio, a

Category iconPress releases

May 1, 2025

Microphysiological systems for mAbs development: how do they address animal limitations?

Welcome to part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs),

Category iconBlog

May 1, 2025

Why the FDA animal testing phase-out for monoclonal antibodies?

In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal

Category iconBlog

April 24, 2025

CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform

CN Bio and Pharmaron partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel

Category iconPress releases

Primary Sidebar

Filter news

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio adds computational modelling capabilities to ADME services for enhanced bioavailability profiling September 1, 2025
  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
Cyber Essentials Logo